NRICM101 has revealed positive outcome in COVID-19 treatment clinically. Pharmacological studies have confirmed that it can neutralize the SARS-CoV-2, block virus infection, inhibit virus growth,reduce the occurrence of cytokine storms. NRICM101 has been non-exclusively authorized by 8 Taiwanese GMP-certified TCM pharmaceuticals. At present, NRICM101 is seeing an increasing worldwide demand,has received Emergency Use Authorization from the Ministry of HealthWelfare of Taiwan. Asymptomaticmildly ill patients of COVID-19 are expected to benefit from it.

NRICM101 is characterized with its antiviralimmunomodulatory ability. Three advantages of this invention are worth highlighting: (1) it can be mass producedconveniently administered, enhancing acceptability in localoverseas market (2) the supply of raw materials is guaranteed (3) it can be used for both preventiontreatment. In addition, we only work with GMP-certified TCM pharmaceuticalsensure consistent quality of NRICM101.

It is estimated that 3.5 million people will use NRICM101to treat COVID-19 within 5 years, which can create an output value of nearly NT$20 billion. According to the TCM theory, NRICM101 can also exert therapeutic effect for influenza, which indicates a more profitable prospect greater than NT$20 billion.

天使投資人、策略合作夥伴